What the coming year might hold for biopharma
Big events for 2021 include the FDA’s decision on aducanumab and pivotal readouts in diabetes and autoimmunity, while investor enthusiasm will be closely monitored.
Ash 2020 – IGM averts disaster, but competition looms
Sellside firefighting has saved the day for IGM, but Ash hears of some pretty potent anti-CD20 competition for the company.
Go or no go? The year ends with Covid-19 vaccine approvals in sight
December promises big US decisions for Novartis, Astrazeneca and Fibrogen, as well as the FDA's first Covid-19 vaccine reviews.
Glaxo moves up a place in the RSV treatment race
The start of a pivotal trial of Glaxosmithkline’s RSV vaccine adds another late-stage project to the pipeline for this underserved disease category.
Ash 2020 preview – Novartis touts its Tasigna follow-on
Pivotal data at the upcoming Ash conference make Novartis’s asciminib one of the highlights for oncology watchers.
For severe Covid-19 pin your hopes on antibodies
Failure of BTK inhibition puts the pressure on Lilly, Regeneron and Astrazeneca to deliver with antibodies to treat severe Covid-19.
Chemocentryx takes a leap of faith with avacopan
Despite the phase II failure, Chemocentryx is pushing on in hidradenitis suppurativa.
